Accessibility Menu
InMed Pharmaceuticals Stock Quote

InMed Pharmaceuticals (NASDAQ: INM)

$1.26
(0.8%)
+0.01
Price as of December 23, 2025, 4:00 p.m. ET

KEY DATA POINTS

Current Price
$1.26
Daily Change
(0.8%) +$0.01
Day's Range
$1.23 - $1.32
Previous Close
$1.26
Open
$1.23
Beta
1.32
Volume
48,367
Average Volume
352,024
Market Cap
$1.5M
Market Cap / Employee
$1.25M
52wk Range
$1.13 - $8.27
Revenue
N/A
Gross Margin
0.22%
Dividend Yield
N/A
EPS
-$6.91
CAPs Rating
N/A
Industry
Pharmaceuticals

The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More

InMed Pharmaceuticals Return vs. S&P

1 Year5 Year5 Year AnnualizedSince IPO
INM-73.08%-99.92%-75.96%-100%
S&P+15.66%+86.6%+13.29%+270%
Advertisement

InMed Pharmaceuticals Company Info

InMed Pharmaceuticals, Inc. engages in the provision of biopharmaceutical research. It is also involved in cannabinoid-based therapies and a biosynthesis system for the manufacturing of pharmaceutical-grade cannabinoids. The company was founded by Christopher Bogart, Sazzad Hossain, Hyder A. Khoja, and Craig D. Schneider on May 19, 1981 and is headquartered in Vancouver, Canada.

News & Analysis

No results found

No news articles found for InMed Pharmaceuticals.

Financial Health

General

Q3 2025YOY Change
Revenue$1.12M-11.4%
Gross Profit$246.48K-29.3%
Gross Margin22.00%-5.5%
Market Cap$2.64M-16.4%
Market Cap / Employee$203.36K0.0%
Employees130.0%
Net Income-$1,726.90K-2.9%
EBITDA-$1,606.99K0.1%

Currently no data to display

Revenue Growth Rate

Currently no data to display.

Earnings Per Share Growth Rate

Currently no data to display.

Assets

Q3 2025YOY Change
Net Cash$9.33M67.1%
Accounts Receivable$343.47K20.6%
Inventory0.9-27.0%

Liabilities

Q3 2025YOY Change
Long Term Debt$215.48K-66.0%
Short Term Debt$424.77K0.1%

Ratios

Q3 2025YOY Change
Return On Assets-68.93%-5.2%
Return On Invested Capital-106.86%17.3%

Cash Flow

Q3 2025YOY Change
Free Cash Flow-$1,607.62K12.0%
Operating Free Cash Flow-$1,607.62K12.0%

Valuation

MetricQ4 2024Q1 2025Q2 2025Q3 2025YoY Change
Price to Book0.380.240.560.33-13.33%
Price to Sales0.690.461.321.80204.61%
Price to Tangible Book Value0.480.330.730.37-93.48%
Enterprise Value to EBITDA-0.400.812.260.05-95.50%
Return on Equity-83.5%-91.7%-72.1%-82.2%8.33%
Total Debt$948.96K$848.59K$741.26K$640.24K-39.49%

No results found

No podcast episodes available.

No results found

No transcripts available.

Advertisement

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.